



Retrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100

August 3, 2020

SAN DIEGO (August 3, 2020) – Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., president and chief executive officer, has been named by PharmaVOICE magazine to the 2020 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry. Dr. Dube has been acknowledged for his commitment to patients with unmet needs, and his leadership in building momentum for diversity and inclusion in the industry.

Under Dr. Dube's leadership, Retrophin is advancing its late-stage therapeutic candidate sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. There are no currently approved medicines indicated for FSGS and IgAN, and the disorders affect a high proportion of Black, Latinx and Asian patients. Dr. Dube recognizes there is a lack of equitable access to information, clinical trials, diagnosis and treatments for diverse patients in the rare community.

With his vision, Retrophin became the founding sponsor of the Rare Disease Diversity Coalition led by the Black Women's Health Imperative to address racial disparities in the health care system, access issues, coverage and affordability. Retrophin's support also led to the initiation of the first-ever Diversity Inclusion Advocacy Fellowship at the EveryLife Foundation for Rare Diseases to increase the representative diversity of patient voices and to engage low income and minority communities in advocacy.

"As a member of the LGBTQI community, and having worked extensively in communities of color, I have seen the high degree of unmet needs and barriers to innovation that exist," Dr. Dube reflected in the interview with PharmaVOICE magazine. "As life science leaders, we have a duty to innovate and address these issues. It is truly an honor to be recognized among these inspiring individuals," said Dr. Dube.

Now in its 15th year, the PharmaVOICE 100 celebrates people in the life sciences industry who have inspired their peers, colleagues and companies through their innovative approaches and strong leadership.

To view Dr. Dube's full PharmaVOICE 100 profile, [visit the July/August 2020 online edition](#).

About Retrophin

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company's approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin's R&D efforts are supported by revenues from the Company's commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.

Retrophin.com

Contact:

Chris Cline, CFA

Senior Vice President, Investor Relations & Corporate Communications

888-969-7879

IR@retrophin.com